Document is current
Any future updates will be listed below
-
Authors
Oh, Chang-ki https://orcid.org/0000-0003-2489-4072
Nakamura, Tomohiro
Beutler, Nathan
Zhang, Xu
Piña-Crespo, Juan
Talantova, Maria
Ghatak, Swagata
Trudler, Dorit
Carnevale, Lauren N. https://orcid.org/0000-0003-0451-0481
McKercher, Scott R.
Bakowski, Malina A.
Diedrich, Jolene K.
Roberts, Amanda J.
Woods, Ashley K.
Chi, Victor
Gupta, Anil K.
Rosenfeld, Mia A. https://orcid.org/0000-0002-8961-8231
Kearns, Fiona L.
Casalino, Lorenzo https://orcid.org/0000-0003-3581-1148
Shaabani, Namir
Liu, Hejun https://orcid.org/0000-0002-2412-7853
Wilson, Ian A. https://orcid.org/0000-0002-6469-2419
Amaro, Rommie E. https://orcid.org/0000-0002-9275-9553
Burton, Dennis R. https://orcid.org/0000-0001-6711-9864
Yates, John R. III https://orcid.org/0000-0001-5267-1672
Becker, Cyrus https://orcid.org/0000-0001-7868-464X
Rogers, Thomas F.
Chatterjee, Arnab K. https://orcid.org/0000-0001-5171-7982
Lipton, Stuart A. https://orcid.org/0000-0002-3490-1259
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (RF1 AG057409, R01 AG056259, R01 DA048882, R35 AG071734, DP1 DA041722, R61 NS122098, RF1 NS123298, R01 AG061845, T32AI007384, T32 EB009380, R01 GM132826, UM1 AI144462, P41 GM103533)
California Institute for Regenerative Medicine (DISC2 COVID19-11811)
COVID-19 awards from Fast Grants
Bill and Melinda Gates Foundation (INV-004923)
National Science Foundation (MCB-2032054)
the RCSA Research Corp. and a UC San Diego Moore’s Cancer Center 2020 SARS-CoV-2 seed grant
Bill and Melinda Gates Institute for Population and Reproductive Health (OPP1107194)
- License Information
-
More Information
Article History
Received: 7 March 2022
Accepted: 24 August 2022
First Online: 29 September 2022
Competing interests
: The authors declare that S.A.L. is an inventor on patents for the use of memantine and various aminoadamantane nitrate compounds for neurodegenerative and neurodevelopmental disorders. He is also an inventor on composition of matter patents and use patents for aminoadamantane nitrate compounds in treating COVID-19 and other viral diseases. Per Harvard University guidelines, S.A.L. participates in a royalty-sharing agreement with his former institution, Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda) to Forest Laboratories/Actavis/Allergan/AbbVie for use in dementia. The aminoadamantane nitrate compounds have been licensed to EuMentis Therapeutics. C.B. is a chemist employed at EuMentis Therapeutics. The other authors declare no financial conflicts of interest relevant to this publication.
Free to read: This content has been made available to all.
